Avant Diagnostics Inc fka AVDX

[MikeCr]

InterVenn BioSciences Raises $9.4M in Funding
Dec 12, 2018 | staff reporter
NEW YORK (GenomeWeb) – Diagnostics company InterVenn BioSciences said today it has raised $9.4 million in a funding round led by Genoa Ventures.

The Redwood City, California-based firm will use the funds to develop its lead product, a mass spectrometry-based blood test for ovarian cancer. The company said it is currently doing analytical and clinical validation for the test, which it ultimately plans to offer as a laboratory-developed test.

https://www.genomeweb.com/business-news/intervenn-biosciences-raises-94m-funding#.XBGp8mhKjIU

And yet over 10 years Avant was not able to raise any money to fund the OvaDx ovarian cancer test that they say is supposed to be so accurate.
Hmmm I wonder why?